A5101749555- Lung Cancer Treatments and Mutations
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Ubiquitin and proteasome pathways
- PI3K/AKT/mTOR signaling in cancer
- Cancer Genomics and Diagnostics
- Functional Brain Connectivity Studies
- Pharmacogenetics and Drug Metabolism
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Pharmaceutical studies and practices
- Epilepsy research and treatment
- Colorectal Cancer Treatments and Studies
- MicroRNA in disease regulation
- Ginseng Biological Effects and Applications
- Hedgehog Signaling Pathway Studies
- Cancer Treatment and Pharmacology
- Occupational and environmental lung diseases
- Infectious Encephalopathies and Encephalitis
- Advanced MRI Techniques and Applications
- Histone Deacetylase Inhibitors Research
- Traditional Chinese Medicine Studies
- Parvovirus B19 Infection Studies
China Medical University
2014-2024
Bristol-Myers Squibb (United States)
2021-2023
Jiangxi University of Traditional Chinese Medicine
2023
Nanchang Institute of Science & Technology
2023
St. Vincentius-Kliniken
2014
Asklepios Fachkliniken München-Gauting
2014
Heidelberg University
2014
University Hospital Heidelberg
2014
Bristol-Myers Squibb (Switzerland)
2014
St. Jude Children's Research Hospital
2012-2013
Medulloblastoma is a malignant childhood brain tumour comprising four discrete subgroups. Here, to identify mutations that drive medulloblastoma, we sequenced the entire genomes of 37 tumours and matched normal blood. One-hundred thirty-six genes harbouring somatic in this discovery set were an additional 56 medulloblastomas. Recurrent detected 41 not yet implicated medulloblastoma; several target distinct components epigenetic machinery different disease subgroups, such as regulators H3K27...
Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in small-cell lung cancer (SCLC) phase trials. This III trial compared the safety efficacy of amrubicin versus topotecan as second-line treatment for SCLC.A total 637 patients with refractory or sensitive SCLC were randomly assigned at ratio 2:1 to 21-day cycles 40 mg/m(2) intravenously (IV) on days 1 3 1.5 IV 5. Primary end point was overall survival (OS); secondary points included...
Despite recent progress, multiple myeloma remains incurable. Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of myeloma, including those resistant to lenalidomide pomalidomide. In this phase 1–2 study, we administered oral mezigdomide combination dexamethasone patients relapsed refractory myeloma. The primary objectives 1 (dose-escalation cohort) were assess safety pharmacokinetics identify the dose...
This first-in-human Phase I study investigated the safety, pharmacokinetics (PK), pharmacodynamic profile, and preliminary efficacy of CC-115, a dual inhibitor mammalian target rapamycin (mTOR) kinase DNA-dependent protein kinase.Patients with advanced solid or hematologic malignancies were enrolled in dose-finding cohort expansion phases. In dose-finding, once-daily twice-daily (BID) ascending oral doses CC-115 (range: 0.5-40 mg/day) 28-day continuous cycles identified maximum-tolerated...
Glioblastoma is the most common and aggressive malignant primary brain tumor in humans, accounting for 52 % of all functional tissue cases 20 intracranial tumors. The typical treatment involves a combination chemotherapy, radiation, surgery, whereas it still achieves fairly poor patient survival. Ginsenoside Rh2 has been reported to have therapeutic effect on some tumors, but its glioblastoma not extensively evaluated. Here, we show that ginsenoside can substantially inhibit growth vitro...
Impairment of intrinsic plasticity is involved in a range neurological disorders such as epilepsy. However, how excitability regulated still not fully understood. Here we report that the epigenetic factor Chromodomain Y-like (CDYL) protein critical regulator initiation and maintenance neuroplasticity by regulating voltage-gated ion channels mouse brains. CDYL binds to regulatory element intron region SCN8A mainly recruits H3K27me3 activity for transcriptional repression gene. Knockdown...
The optimal total number of docetaxel cycles in patients with metastatic castration resistant prostate cancer (mCPRC) has not been investigated yet. It is unknown whether it beneficial for to continue treatment upon 6 cycles.To investigate the administered deriving clinical benefit was an independent prognostic factor overall survival (OS) a post hoc analysis Mainsail trial.The trial multinational randomized phase 3 study 1059 mCRPC receiving docetaxel, prednisone, and lenalidomide (DPL) or...
Background This study was designed to assess changes in brain volume and cognitive abilities memantine‐treated patients with Alzheimer's disease (AD) by using an exploratory, single‐arm, delayed‐start design. Methods Cholinesterase inhibitor‐treated AD (N = 47; Mini‐Mental State Examination score range: 15–23) were enrolled observational lead‐in period (weeks: 1–24), followed open‐label of add‐on memantine treatment 25–48). The underwent magnetic resonance imaging at weeks 0 (baseline), 24...
Being the most malignant primary brain tumor in humans, glioblastoma multiforme (GBM) has a fairly poor patient survival after current combined treatment with chemotherapy, radiation, and surgery. Ginsenoside Rh2 (GRh2) been reported to have therapeutic effect on some tumors, we recently its inhibitory GBM growth vitro vivo, possibly through an epidermal factor receptor (EGFR) signaling pathway. Here, using specific inhibitors, found that activation of EGFR promoted PI3k/Akt/mTor pathways....
2035 Background: Almost 80% of adult medulloblastoma are the SHH subtype. Second line therapy for MB is limited; therefore we tested efficacy vismodegib, a small molecule inhibitor Smoothened (SMO) among patients with this disease. Methods: Adult refractory or recurrent and who had measureable disease were enrolled on study. Immunohistochemistry (IHC) was used to stratify Stratum A (non-SHH group); B (SHH tumors) C (indeterminate). All treated vismodegib at 150 mg/day PO daily. Tumor...
In recent times, disulfidptosis, an intricate form of cellular demise, has garnered attention due to its impact on prognosis, tumor progression and treatment response. Nevertheless, the exact significance disulfidptosis-related genes (DisRGs) in glioblastoma (GBM) remains enigmatic. The GEO TCGA databases provided transcriptional clinically relevant data samples, while GTEx database healthy tissues. Disulfidptosis-related were procured from previous scholarly investigations. expression...
Objective: This study investigated whether pre-operative interictal discharge patterns detected by electroencephalogram (EEG) and magnetic resonance imaging (MRI) findings affect the surgical prognosis in temporal lobe epilepsy (TLE) patients. Methods: A retrospective analysis of 115 cases patients with refractory TLE was carried out from October 2010 to 2014 based on classification EEG MRI findings. The were followed up for 4 years after surgery. ILAE method used assess differences...
In order to improve the safety of lumbar puncture (LP), we designed a new type LP needle, that is, an integrated and controlled which can actively accurately control flow rate retention cerebrospinal fluid (CSF) during puncture, so as achieve procedure.To evaluate whether procedure comfort reduce risk complications associated with LP.Patients requiring (n = 63) were pierced needle or conventional needle. The differences in vital signs, symptom score, comfort, operation time, CSF loss,...
Simple febrile convulsion (SFC) is a common disease that mainly caused by fever from extracranial infections. In this study, we used proteomic approaches involving discovery and validation cohorts to examine the proteomes of serum children who were diagnosed with SFC, but without convulsion, healthy (normal controls). We identified 86 proteins involved in different biological pathways significantly between SFC normal control groups. Of these proteins, 35 had higher expression group compared...
<div>Abstract<p><b>Purpose:</b> This dose-finding phase I study investigated the maximum-tolerated dose (MTD) and safety of weekly nanoparticle albumin-bound rapamycin (<i>nab</i>-rapamycin) in patients with untreatable advanced nonhematologic malignancies.</p><p><b>Experimental Design:</b><i>nab</i>-Rapamycin was administered for 3 weeks followed by 1 week rest, a starting 45 mg/m<sup>2</sup>. Additional...
<div>Abstract<p><b>Purpose:</b> This dose-finding phase I study investigated the maximum-tolerated dose (MTD) and safety of weekly nanoparticle albumin-bound rapamycin (<i>nab</i>-rapamycin) in patients with untreatable advanced nonhematologic malignancies.</p><p><b>Experimental Design:</b><i>nab</i>-Rapamycin was administered for 3 weeks followed by 1 week rest, a starting 45 mg/m<sup>2</sup>. Additional...
<p>Mesothelioma patient molecular profile from biopsy: A) Immunohistochemical staining of phosphatase and tensin homolog (PTEN); B) Single-nucleotide polymorphism on PH domain leucine-rich repeat protein 2 (PHLPP2)</p>
<p>Supplementary Figure legend</p>
<p>A) Association of PBMC 4EBP1 T70 levels with serum rapamycin concentrations; B) S6K T389 concentrations</p>
<p>Mesothelioma patient molecular profile from biopsy: A) Immunohistochemical staining of phosphatase and tensin homolog (PTEN); B) Single-nucleotide polymorphism on PH domain leucine-rich repeat protein 2 (PHLPP2)</p>
<p>A) Association of PBMC 4EBP1 T70 levels with serum rapamycin concentrations; B) S6K T389 concentrations</p>